Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Mosunetuzumab, RUO) (HY257166)

Name: Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Mosunetuzumab, RUO)
Brand: abinScience
SKU: HY257166
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HY257166
Descripción	Research Grade Mosunetuzumab (HY257166) is a humanized monoclonal antibody detecting B-lymphocyte surface antigen B1 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Aplicaciones probadas	WB
Objetivo	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1, CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P11836 & P07766
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	Bispecific, BTCT4465A, RG-7828, RO7030816, 1905409-39-3
Fondo	Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Mosunetuzumab
Bioactivity

Detects Human CD20/MS4A1 & CD3E separately in indirect ELISAs.
Bioactivity

Detects Human CD20/MS4A1 & CD3E separately in indirect ELISAs.
Western blot

Western blot analysis was performed using anti-CD3E monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD3E (Catalog No: HY057011)
Lane 2: negative control